Bryant Furlow

Contributing Writer https://www.cancertherapyadvisor.com

Bryant Furlow is a contract medical journalist for the Haymarket Medical Network. He holds a bachelor of science in biology (summa cum laude) from the University of New Mexico. He covers radiation oncology, immunotherapy, tumor biology, clinical research, and health care policy. Prior to becoming a contributor to Haymarket Media in 2010, Bryant was a newspaper reporter in New Mexico, where he won awards for public health and investigative journalism. He also reports for The Lancet Oncology news desk.

All articles by Bryant Furlow

ASH 2019

Frontline Bendamustine Plus Rituximab Deemed “Highly Effective” in Waldenström Macroglobulinemia

Bryant Furlow

December 9, 2019

There was no benefit observed with the use of rituximab in the maintenance setting in Waldenström macroglobulinemia.

Tosedostat with cytarabine or decitabine induced complete remission in AML/MDS.

ASH 2019

CXCR4 Mutations Do Not Impact Progression-Free Survival in Waldenström Macroglobulinemia Patients Treated With Proteasome Inhibitors

Bryant Furlow

December 9, 2019

No detectable differences were found in major response rate at 6 months and 12 months between patients with and without CXCR4 mutations.

ASH 2019

Real-World Sequence Patterns of Novel Agents in CLL Described

Bryant Furlow

December 9, 2019

More than half of the patients with CLL included in the retrospective study first received a novel agent in the second-line setting.

Researchers conducted a meta-analysis of 4 studies examining prophylaxis with factor VIII or emicizumab for hemophilia A without inhibitors.

ASH 2019

Nonrelapse Mortality in B-Cell Lymphomas “Should Be Reported Prospectively,” According to Researchers

Bryant Furlow

December 8, 2019

The researchers determined that in FAERS, a greater proportion of cytokine release syndrome occurred with axi-cel.

Patients with concurrent diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma were more likely to have germinal center B-cell-like DLBCL.

ASH 2019

Bridging Therapy Prior to CAR-T Is Not Recommended for All Patients With Lymphoma

Bryant Furlow

December 8, 2019

Researchers noted that bridging while awaiting CAR-T manufacturing may not be appropriate for all patients, and in some cases, bridging was associated with worse PFS and OS.

ASH 2019

Promising First-Line Immunotherapy Findings in Hodgkin Lymphoma: Complete Response of 100%

Bryant Furlow

December 7, 2019

The study yielded a complete response rate of 100% across 33 subjects.

General Oncology

Gender Bias in Oncology: Q&A With Dr Narjust Duma

Bryant Furlow

November 26, 2019

Women are less likely to be introduced by their professional title and most likely to be introduced by first name.

Many recent vaping injuries have been linked to e-cigarette use of THC oils or other cannabis oil products, raising new concerns about patients with cancer who use the devices for medical marijuana.

Lung Cancer

Vaping Injuries Raise New Concerns About Medical Marijuana

Bryant Furlow

November 11, 2019

Many recent vaping injuries have been linked to e-cigarette use of THC oils or other cannabis oil products, raising new concerns about patients with cancer who use the devices for medical marijuana.

General Oncology

Tools for Assessing, Managing Elderly With Cancer for Malnutrition

Bryant Furlow

November 8, 2019

This review discusses nutritional interventions and management of nutritional status in elderly patients with cancer.

$Ultrahypofractionated SBRT can deliver radiotherapeutic doses in 2 weeks or fewer without increasing toxicity risk, according to findings from PACE-B.$

Prostate Cancer

Ultrahypofractionated SBRT Prostate Cancer Radiotherapy Does Not Increase Radiotoxicities

Bryant Furlow

November 5, 2019

Ultrahypofractionated SBRT can deliver radiotherapeutic doses in 2 weeks or fewer without increasing toxicity risk, according to findings from PACE-B.

Next post in Prostate Cancer